, for the TODAY Study Group † Objectives Data regarding atherogenic dyslipidemia and the inflammation profile in youth with type 2 diabetes is limited and the effect of insulin therapy on these variables has not previously been studied in youth. We determined the impact of insulin therapy on lipid and inflammatory markers in youth with poorly controlled type 2 diabetes.
T he increasing prevalence of type 2 diabetes in youth is expected to contribute to an increase in diabetes-related complications, including cardiovascular disease. 1, 2 This concern is heightened by the high prevalence of cardiovascular risk factors and markers of cardiovascular end organ injury in this population. 3 The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial was a multicenter, randomized clinical trial (ClinicalTrials.gov: NCT00081328) designed to compare the effect of 3 treatment regimens to maintain glycemic control in youth with recent-onset type 2 diabetes. The TODAY cohort provides a unique opportunity to examine the effects of insulin therapy in youth with type 2 diabetes with poor glycemic control on metformin (rosiglitazone was stopped upon insulin initiation). In light of the known accordance between glycemic control with dyslipidemia and markers of inflammation, we set out to explore the impact of reaching the primary outcome with subsequent initiation of insulin on these variables.
The objective of the current study was to determine the impact of insulin therapy on lipid profiles and inflammatory markers in the TODAY participants who reached primary outcome. We hypothesized that insulin therapy would ameliorate lipid abnormalities and chronic inflammation in obese youth with type 2 diabetes, related to improved glycemic control.
Methods
Details regarding the TODAY study design and methods have been reported. 4, 5 In brief, 699 youth 10-17 years of age were enrolled between July 2004 and February 2009. Participants had type 2 diabetes of <2 years' duration using criteria of the American Diabetes Association, a body mass index (BMI) ≥85th percentile for age and sex, and negative pancreatic autoantibodies. Patients with refractory hyperlipidemia (n = 2)-total cholesterol >300 mg/dL or low-density lipoprotein cholesterol (LDL-C) of >190 mg/dL or triglycerides >800 mg/dL, despite appropriate medical therapy, were excluded from participation in the study. After randomization, participants were seen every 2 months in the first year and quarterly thereafter. Glycated hemoglobin A1c (HbA1c) was assessed at each visit and other laboratory measures including fasting lipid and inflammatory markers were determined at baseline, 6 months, and annually. The TODAY protocol was approved by the institutional review boards at each participating institution. Parents of children and adolescents provided written informed consent; children and adolescents provided assent.
When participants reached the primary outcome, metformin was continued, rosiglitazone was discontinued in the metformin plus rosiglitazone group, and insulin was added. After the initiation of insulin therapy, participants and clinicians remained masked to the original treatment assignment, but were unmasked to HbA1c. Initial insulin treatment was 0.2 U/kg glargine insulin each evening and was increased up to 1.0 U/kg/d (maximum 100 U) until fasting blood glucose levels reached 70-150 mg/dL.
Lipid-lowering medications, primarily atorvastatin, were initiated for persistent LDL-C levels of ≥130 mg/dL or triglyceride levels of 300-599 mg/dL after 6 months of nutrition and diabetes management per algorithm. 4 If triglycerides were ≥600 mg/dL, fibrate therapy could be initiated at the discretion of the physician, in addition to invigorating measures to achieve glycemic control, given the known relationships between hypertriglyceridemia and hyperglycemia.
Of the 699 TODAY participants, 34 of the 319 who reached the primary outcome were excluded from the preset analysis (12 had ≥1 full-term/preterm pregnancies, 1 required multiple episodes of temporary insulin treatment, and 21 reached primary outcome but never received insulin, that is, they reached the primary outcome right before the end of the study or were lost to follow-up after reaching the primary outcome).
Comparison of these 21 excluded participants with the 285 included in the sample showed that those lost to follow-up were more likely to be male (13 of 21 [62%] were male vs 37% among the 285; P = .0250), but were not found different with respect to age at baseline, race/ethnicity, baseline Tanner stage, socioeconomic status (highest level of household education and income), duration of diabetes, baseline BMI, or baseline HbA1c. There were 363 TODAY participants who maintained glycemic control during the study and never started insulin.
All samples were shipped on dry ice to the Northwest Lipid Research Laboratory, University of Washington, Seattle, Washington. The methods and analytical performance for determination of HbA1c, lipids, separation of LDL-C fractions, apolipoprotein B (apoB) in plasma and in LDL-C fractions, plasma nonesterified fatty acids (NEFA), high-sensitivity C-reactive protein (hs-CRP), plasminogen activator inhibitor-1 (PAI-1), and homocysteine were described previously. 4 Analysis of interleukin-6 (IL-6) was performed using the human highsensitivity magnetic beads-based method (EMD Millipore Inc, Billerica, Massachusetts). The assay sensitivity was 0.18 pg/ mL. The intra-assay and interassay coefficients of variation were 7% and 8%, respectively, for the low-quality control samples and 6.8% and 8.4%, respectively, for the high-quality control.
Height (cm) and weight (kg) were measured as previously described 4 and used to calculate BMI in kg/m 2 . Percent overweight, a weight-related metric measure now widely used for describing and tracking heavier children, 6 was defined as BMI minus BMI at the 50th percentile for age and sex based on Centers for Disease Control and Prevention growth charts, divided by BMI at the 50th percentile, times 100.
Statistical Analyses
Data are presented as mean and SD or percent. We used c 2 tests or t tests to compare demographic and laboratory characteristics at time 0 between the TODAY participants who reached primary outcome and those who never reached it. For the group who reached the primary outcome, time 0 was defined as the date long-term insulin therapy was started; for those who did not reach the primary outcome, time 0 was defined as the midpoint in the study, resulting in equal duration in the study in the 2 groups.
Piecewise random coefficient modeling was used, 7, 8 which allows for comparison of trends (slopes reflecting a change in outcome over time) corresponding with time before and time after a defined time 0. This method is appropriate for repeated measures data collected at uneven time intervals and allows for covariate adjustment.
SAS PROC MIXED (SAS version 9.3, SAS Institute Inc, Cary, North Carolina) was used to fit the piecewise random coefficient model. The model consisted of regressing each lipid or inflammatory marker outcome variable as a function of time relative to time 0, thereby obtaining 1 intercept (at time 0) and 2 slopes (one before and one after time 0) for each participant. The 2 times (relative to time 0) were included in the model as random effects. Intraclass correlations coefficients were calculated for each random effects model. The intraclass correlations coefficients obtained ranged from 55% to 71% for the Volume 196 • May 2018 lipid models and ranged from 45% to 74% for the inflammatory marker models, suggesting some degree of betweensubject variance in the observations. The impact of HbA1c and percent overweight was also examined by evaluating models with or without HbA1c and/or percent overweight as timevarying covariates. Randomized treatment group was also considered as a covariate in our analysis, but not retained in the final models because it was not found to be a significant contributor in any of the models. Data were included up to 3 years before and 3 years after time 0. A parallel analysis was performed on the dichotomous outcome LDL-C particle density (cutoff at relative flotation rate of ≤0.263) using SAS PROC GENMOD and testing for trends in percentages over time rather than slopes.
Extreme values in the distribution of each outcome (defined as <1st and >99th percentiles) were set to missing. Values were used even if the participants were placed on lipid-lowering medications or antihypertensive medications during the study.
PAI-1, hs-CRP, homocysteine, IL-6, and triglycerides were log-transformed before modeling owing to a lack of normality. High-density lipoprotein cholesterol (HDL-C) analyses were performed separately for each sex. Interaction terms of subgroup variables of interest with the preinsulin and postinsulin slopes were added to the models to assess differences by race/ ethnicity, sex, and parental history of dyslipidemia or cardiovascular disease. All analyses were considered exploratory, and P < .05 was considered statistically significant; the study was powered for the primary outcome only.
Results
Participant demographic and laboratory characteristics at the time long-term insulin therapy was started (time 0) in the group that experienced the primary outcome are shown in Table I . These characteristics were compared with those from participants who maintained glycemic control and never started ns, non-significant (P > 0.05).
Medians are reported and compared using the Wilcoxon 2-sample test for months from randomization to time 0. For the group who reached primary outcome, time 0 was defined as the date long-term insulin therapy was started; for those who did not reach primary outcome, time 0 was defined as the midpoint in the study. Biological parental history of dyslipidemia (high cholesterol/ high fat) and cardiovascular disease (stroke/heart attack) were obtained from the parent or other knowledgeable family member via self-report at the baseline visit. Laboratory values could not be obtained within 3 months of time 0 for all participants, resulting in 15% missing laboratory values for the reached primary outcome group and 30% missing values for the never reached primary outcome group. Values are mean ± SD or %. *Statistics were calculated on the original scale; P values were based on tests performed on log-transformed values to normalize the distribution.
THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 196 insulin, using data collected at an equivalent time point in the study as time 0. Participants starting insulin therapy had higher levels of total cholesterol, triglycerides, apoB, apoB in LDL-C fractions, cholesterol in LDL-C fractions, PAI-1, hs-CRP, and IL-6 compared with those not requiring insulin. Because the changes in the lipid profiles and inflammatory markers over time in participants who never reached primary outcome (maintained glycemic control) have been previously reported, 9 the remainder of the analyses focused on the group of participants who reached primary outcome and started insulin therapy during the study.
Total cholesterol, LDL-C, cholesterol in LDL-C fractions, and total apoB increased before insulin therapy (Figure 1, A-D) . The increase continued after insulin initiation, but at a reduced rate; slopes before and after starting insulin were significantly different (Table II) . After adjustment for HbA1c and percent overweight, slopes were reduced and differences in slopes before vs after insulin initiation were no longer significant. Triglycerides (Figure 1 , E) increased before insulin therapy and stabilized after starting insulin; significance did not change with HbA1c and percent overweight in the model. HDL-C concentrations in females were increasing before time 0 and became flat after beginning insulin; slopes for HDL-C in males were uniformly flat (Figure 1, F and G) . The slope for apoB in LDL-C fractions stabilized after time 0 (Figure 1, H) . None of these changes were significant in the adjusted models. The ratio of apoB to cholesterol in LDL-C fractions was significantly different before vs after time 0 in the unadjusted model only (Figure 1, I ). The addition of HbA1c attenuated these relationships.
The percent of subjects with small dense LDL-C particles increased significantly from 60.5% at 1 year before time 0 to 75.9% at insulin start (P < .0001), and then stabilized after time 0 (P = ns). This increase before start of insulin was significant in the unadjusted model (P = .0077) but not in the model adjusted for HbA1c.
In the unadjusted model, NEFA levels increased before insulin initiation and then flattened (the change in slope before vs after was significant [P = .0045]; Figure 1 , J and Table II) . After adjusting for HbA1c and percent overweight, the difference in slopes before vs after time 0 was no longer significant.
PAI-1 and hs-CRP (Figure 2 , A and B) concentrations were increasing significantly before the start of insulin therapy. PAI-1 decreased after starting insulin therapy (significant negative slope) and slopes before vs after time 0 were significantly different in both the unadjusted and adjusted models (Table II) . Hs-CRP continued to increase after starting insulin, but the before vs after time 0 slopes were not different in the adjusted model, after taking into account HbA1c and percent overweight. Homocysteine and IL-6 (Figure 2 , C and D) increased significantly both before and after insulin initiation, but the differences were only significant for homocysteine in the adjusted model. Percent overweight was a significant covariate (P < .0001) along with HbA1c in all inflammatory markers models except for homocysteine.
We further evaluated the effect of reduction in HbA1c on lipids and inflammatory markers after start of insulin therapy.
After 6 months of insulin therapy, the decrease in HbA1c in those with the primary outcome was approximately −0.11% (SD 2.1%). In addition, 40.2% decreased their HbA1c by ≥0.5%, and 27.6% of participants decreased their HbA1c by ≥1%. Analyses were then performed for 2 groups based on change in glycemia: those who achieved a ≥1% reduction in HbA1c after 6 months on insulin vs those who did not (Table III; available at www.jpeds.com). Overall, the slopes for the lipid and inflammatory markers after insulin initiation decreased after insulin initiation in those with decrease in HbA1c of ≥1%. Those with less of a change in HbA1c showed a smaller decrease in cardiovascular disease risk markers after insulin initiation.
The use of prescribed lipid-lowering medications increased in those with the primary outcome from 8.6% at time 0 to 22.0% 1 year later. The percentage of participants prescribed lipid-lowering medications showed an increasing trend before and up to time 0 versus a flat trend after time 0 (trend comparison pre vs post: P < .0001 [unadjusted] and P = .0029 [adjusted for HbA1c]). A sensitivity analysis was performed excluding any participant who was prescribed a lipid-lowering medications at any time during the study. The main outcomes remained essentially unchanged (data not shown), raising the possibility of nonadherence with statin therapy in many participants.
Preinsulin (P = .0191) and postinsulin (P = .0061) slope differences by sex were found for hs-CRP, but the sex difference was similar across both time periods (before and after insulin start), with males having overall lower trends over time compared with females, irrespective of insulin use. Lower levels of IL-6 over time were found in males compared with females, but only before insulin start (P = .0069). No differences by sex were found between the slopes for IL-6 after the start of permanent insulin. Similarly, a race/ethnicity difference in the slopes over time was found for LDL-C (P = .0065) between Hispanic and non-Hispanic white participants, but only before the start of insulin (Table IV and Figure 3 ; available at www.jpeds.com). After the start of permanent insulin, the LDL-C differences by race/ethnicity were no longer significant. No other sex or race/ethnicity differences between the slopes before and after insulin start were found for all other lipids, NEFA, PAI-1, and homocysteine (all P > .05).
No differences by parental history of dyslipidemia or cardiovascular disease were found for any of the lipids, NEFA, or the inflammatory markers, except for homocysteine. Preinsulin slope differences (P = .0116) by parental history of cardiovascular disease were found for homocysteine, but only before insulin start, with lower levels of homocysteine found in participants without a parental history of cardiovascular disease. No parental history differences were found between the slopes for homocysteine after the start of permanent insulin (data not shown).
Discussion
Both HbA1c and dyslipidemia contribute to adverse changes in markers of subclinical atherosclerosis in youth with type 2 
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212 diabetes, including carotid intima media thickness and arterial stiffness.
3,10-13 In youth without diabetes, progressive dyslipidemia typical of those with type 2 diabetes is associated with increased indicators of subclinical atherosclerosis in adulthood.
14 Data regarding the atherogenic profile in youth with type 2 diabetes and the effect of insulin therapy in these youth are limited. In adults, type 2 diabetes alone is a risk factor for higher carotid intima media thickness and worsening (1) whether there is a significant slope before time 0, (2) whether there is a significant slope after time 0, and (3) whether there is a significant difference in slopes before vs after time 0. Adjusted models for the lipids were adjusted for HbA1c as a time-varying covariate only. Adjusted models for NEFA and inflammatory markers were adjusted for HbA1c and percent overweight.* P values were based on tests of log-transformed variables to normalize the distribution; slopes were calculated on the original scale. glucose control is associated with progression of subclinical atherosclerosis. 15 The presence of cardiovascular risk factors, including higher LDL-C particle number, is associated with higher carotid intima media thickness. 16 Cardiometabolic risk is also impacted by systemic inflammation, as indicated by levels of biomarkers of systemic inflammation, including hs-CRP, PAI-1, and homocysteine. Of these, hs-CRP is a strong cardiovascular disease risk predictor. 17 Our current study demonstrates that levels of hs-CRP were related to change in HbA1c and increased before and after the start of insulin therapy.
The results in this study show a close relationship between the progression of dyslipidemia and glucose control. Although LDL-C particle number and size were not analyzed, the lipid changes described, including increase in triglycerides and apoB before the initiation of insulin and an increase in the percentage with smaller dense LDL-C particles, are consistent with a higher atherogenic risk in association with poor diabetes control. The increase in NEFA before insulin therapy and its stabilization after insulin initiation is consistent with the effects of insulin on NEFA release and clearance. Elevated NEFA leads to overproduction of very LDL-C particles and their subsequent remodeling after release from the liver. 18 The initiation of insulin therapy seemed to be beneficial in dampening the increase in total cholesterol, LDL-C, apoB, and NEFA mainly through an effect on HbA1c, but the percentage with smaller LDL-C particles did not change, indicating a persistence of the shift to smaller, denser LDL-C particles. Overall, the observed changes in our study are consistent with short-term clinical studies in adults, supporting a favorable effect of insulin therapy on total and atherogenic LDL-C subgroups, when HbA1c is better controlled. With improvement in glycemia, a decrease in apoB secretion and stable or increasing HDL-C may be seen. [19] [20] [21] [22] The mechanisms of insulin action include an effect on the upregulation of cholesteryl ester transfer protein in 1 study 23 and a decrease in large very LDL-C and hepatic lipase activity in another. 21 The increase in triglyceride concentrations before reaching the primary outcome stabilized after insulin therapy, independent of HbA1c. This finding may reflect the effect of insulin on suppressing lipolysis. In support of this hypothesis, a parallel change was observed in NEFA levels. This effect of insulin therapy on decreasing triglycerides is consistent with the findings in the intensive vs standard insulin treatment arms of the Veterans Affairs Cooperative Study in type II Diabetes Mellitus (VA CSDM) 23 and others. 19 The beneficial effect of insulin on the lipid profile was limited, likely related to continued suboptimal glucose control despite insulin therapy, or to inadequate insulin exposure owing to noncompliance. Consistent with this supposition, there was a more marked overall improvement in the slopes for the lipids and inflammatory markers in the subset of participants that showed greater improvement in HbA1c at 6 months after insulin initiation. Simultaneously, the need for lipid-lowering medications increased over time, consistent with worsening of the lipid profile. A main effect of glycemia on the lipids and inflammatory markers trends was verified by a sensitivity analysis that excluded participants who received lipid-lowering medications. This finding is again consistent with findings in the VA CSDM study where the lipid trends in the subcohort not receiving lipidlowering medications were identical to those in the total study population. 23 In addition, results from our sensitivity analysis raise concerns about noncompliance with lipid-lowering medications in these participants.
The combination of hyperglycemia and hyperlipidemia promotes atherogenesis, 24 raising the question of whether insulin therapy needs to be intensified or started earlier in the course of youth-onset type 2 diabetes, along with strategies to improve adherence. Intensive insulin therapy in adult clinical trials of new and poorly controlled diabetes generally show improvements in lipid profiles in type 1 25 and type 2 diabetes, 19, 23 including when combined with metformin. 26 Long-term followup data in adults from the United Kingdom Prospective Diabetes Study show that insulin use was associated with a 15% reduction in myocardial infarction, 24% reduction in microvascular disease, and 13% reduction in death in individuals with type 2 diabetes. 27 However, multiple trials [28] [29] [30] in adults with type 2 diabetes designed to examine the effect of early insulin therapy on cardiovascular events in older individuals (mean age of 63.5 years) were not successful in establishing a clear benefit. 31 In contrast with the TODAY study, these protocols were designed to evaluate intensive insulin therapy in adults with type 2 diabetes, and many participants already had a significant burden of cardiovascular disease. Older adults, in general, also have a greater benefit from metformin therapy than found in the TODAY trial. Thus, therapeutic approaches in older cohorts may not be optimal for youth with type 2 diabetes.
Intensive glucose control needs to be balanced against the potential for greater weight gain with insulin use and promotion of adipogenesis. 32 Although insulin has anti-inflammatory systemic effects, excess weight gain may worsen insulin resistance, interfere with the beneficial effect of insulin, and potentially worsen diabetic dyslipidemia. In support of this hypothesis, excessive weight gain (>4% of body weight) 6 months after the start of insulin therapy in adults with type 2 diabetes (the majority of whom were prescribed an oral glucose-lowering agent [metformin and/or a sulfonylurea]) was associated with increased proinflammatory cytokine production in subcutaneous adipose tissue. 33 Our prior publication 10 indicated that insulin sensitivity was similar in those participants who progressed to insulin use as compared with those who did not. Although adolescents may gain weight and become more insulin resistant during puberty, the majority of subjects were postpubertal ( Table I ). The TODAY cohort was obese, with a mean BMI of 34.9 ± 7.6 kg/m 2 at baseline. 34 BMI did not change by time 0 (Table I) and remained stable over time. The effect of percent overweight on lipids was minimal. Nevertheless, we did find percent overweight to be a significant covariate in the results of inflammatory markers, along with HbA1c; it may, thus, interfere with the positive effect of insulin on inflammation. Interventions that simultaneously lower both glycemia and hyperinsulinemia and treatments to better target obesity may be more beneficial.
THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 196 Limitations to the current analysis include variable followup over time. Insulin therapy was initiated after the primary outcome with insulin glargine. but then individualized with the goal of achieving glycemic control according to the treating physician's discretion based on fasting glucose levels, rather than a target HbA1c. Although we have previously published results of adherence to oral diabetes medication before primary outcome, 35 adherence to cardiovascular risk reduction therapies were not measured and total daily insulin dose cannot be verified. Medication and lifestyle adherence may explain in part the differences in our outcomes compared with adult trials that used intensive insulin treatment for an extended duration.
It is disturbing that the initiation of insulin therapy often slowed or halted but did not correct longitudinal adverse trends in the cardiovascular risk factors measured with the exception of PAI-1. The addition of insulin after failure of oral treatment regimen did not control the HbA1c; as such, insulin has limited effects on lipids and inflammatory makers in the absence of glycemic control. Earlier initiation of insulin therapy, improved adherence, use of newer glycemic control agents, avoidance of excessive weight gain, novel approaches to increasing exercise, and additional lipid-lowering interventions need to be investigated in this high-risk population. (1) whether there is a significant slope before time 0, (2) whether there is a significant slope after time 0, and (3) whether there is a significant difference in slopes before vs after time 0. *P values were based on tests of log-transformed variables to normalize the distribution; slopes were calculated on the original scale. 
